Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is poised for continued growth as shown by their strong performance, strategic acquisitions, and entry into new markets. Their position as a market leader in transplant testing, favorable Medicare coverage, and expansion of their installation and payer coverage all point to positive future prospects. However, the company must also stay adaptable to technological changes to maintain their success in the long run.

Bears say

CareDx is an innovative company with a unique offering in the transplant patient and caregiver market, but its success is heavily reliant on adoption by slow-moving clinicians and healthcare administrators who may have biases towards traditional practices. Despite a recent positive development in coverage for its AlloSure and AlloMap tests, there are still potential challenges with the adoption of other solutions and the company's reliance on a single technology, making it a risky investment with long lead times for commercialization and potential for setbacks.

CareDx (CDNA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 4 analysts, CareDx (CDNA) has a Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.